Death Sentence for the Life Sciences? Only the Humanities Can Save Biomedical Research and the Pharmaceutical Industry

Add to your list(s) Download to your calendar using vCal

• Don Drakeman, Judge Business School Fellow
• Tuesday 17 May 2011, 18:00-20:00
• Cambridge Judge Business School, LT3.

If you have a question about this talk, please contact pb479.

Please email health@jbs.cam.ac.uk to book a place

The future of the pharmaceutical and biotechnology industries – as well as academic biomedical research – depends nearly as much on the humanities as on science and medicine. Someone will have to pay for new high tech/high cost drugs if the U.K. and other countries hope to maintain the economic benefits from these research intensive enterprises. Deciding whether society will pay for them involves difficult questions of justice, fairness and the nature of the common good. It is essential to invest in the humanities disciplines where these issues are studied, and where many political leaders are educated. Failure to do so could threaten funding for corporate and academic research in the life sciences, and impede the development of new treatments for cancer and other diseases.

This talk is part of the Centre for Health Leadership and Enterprise series.

This talk is included in these lists:

• Cambridge Infectious Diseases
• Cambridge Judge Business School, LT3
• Centre for Health Leadership and Enterprise

Note that ex-directory lists are not shown.